MC1568, Class IIa HDAC Inhibitor


Catalog No. size PriceQuantity
M60224-2S 2 mg solid $79
M60224-10S 10mg solid $316

Description

Product Information
Molecular Weight: 314.31
Formula: C17H15FN2O3
Purity: ≥98%
CAS#: 852475-26-4
Solubility: DMSO up to 100 mM
Chemical Name: 3-[5-(3-(3-Fluorophenyl)-3-oxopropen-1-yl)-1-methyl-1H-pyrrol-2-yl]-N-hydroxy-2-propenamide
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

 

Biological Activity:

 

 

MC1568 is a potent and selective inhibitor of class IIa histone deacetylases (HDACs), with IC50 of 100 nM for maize HD1-A. It is 34-fold more selective for HD1-A than HD1-B, 176-fold more selective for class I HDACs. It exhibits tissue-selective inhibition between members of class II deacetylases in vivo; inhibits HDAC4 and HDAC5 in skeletal muscle and the heart without affecting HDAC3 activity. It arrests myogenesis through the stabilization of myocyte enhancer factor 2D (MEF2D)-HDAC3/4 complex. In a recent study of pancreatic explants, MC1568 enhances expression of Pax4, a key factor required for proper β-and δ-cell differentiation and amplifies endocrine β- and δ-cells.


How to Use:

 

 

In vitro:  MC1568 was used at 5-10µM final concentration in vitro and cellular assays.

In vivo: MC1568 could be orally dosed to mice at 50 mg/kg once per day (formulation: 0.5% CMC, 5 mg/mL). It has an apparent tissue-selective HDAC inhibition. In skeletal muscle and heart, MC1568 inhibits the activity of HDAC4 and HDAC5 without affecting HDAC3 activity, thereby leaving MEF2-HDAC complexes in a repressed state.


Reference: 

 

  • 1. Mai A, et al. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. (2005) J Med Chem. 48(9):3344-53.
  • 2. Mai A, et al. Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. (2007) Mol Pharmacol.72(5):1111-23.
  • 3. Duong V, et al. Specific activity of class II histone deacetylases in human breast cancer cells.(2008) Mol Cancer Res.6(12):1908-19.
  • 4. Nebbioso A, et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. (2009) EMBO Rep. 10(7):776-82.
  • 5. Lenoir O, et al. Specific control of pancreatic endocrine β- and δ-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9. (2011) Diabetes. 60(11):2861-71.




Products are for research use only. Not for human use.

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard PayPal Shop Pay Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed